OGN

Organon & Co

OGN, USA

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

https://www.organon.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.02

Next Payout:

Dec 11, 2025

Yield:

1.1158 %
OGN
stock
OGN

How Investors Are Reacting To Organon (OGN) As Barclays Joins Growing Analyst Skepticism simplywall.st

Read more →
OGN
stock
OGN

Is Trending Stock Organon & Co. (OGN) a Buy Now? Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$9.6667

Analyst Picks

Strong Buy

0

Buy

2

Hold

3

Sell

2

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

3.98

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Medium

2.06

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

High

17.66 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

1.18 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Medium

9.30 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

13.96

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 84.86% of the total shares of Organon & Co

1.

Vanguard Group Inc

(12.4161%)

since

2025/06/30

2.

BlackRock Inc

(11.9793%)

since

2025/06/30

3.

iShares Core S&P Small-Cap ETF

(5.9467%)

since

2025/08/31

4.

Massachusetts Financial Services Company

(3.9379%)

since

2025/06/30

5.

State Street Corp

(3.6623%)

since

2025/06/30

6.

Millennium Management LLC

(3.4968%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(3.1228%)

since

2025/07/31

8.

LSV Asset Management

(3.0733%)

since

2025/06/30

9.

Vanguard Small Cap Index

(2.4257%)

since

2025/07/31

10.

UBS Group AG

(2.2925%)

since

2025/06/30

11.

Morgan Stanley - Brokerage Accounts

(2.2104%)

since

2025/06/30

12.

Citadel Advisors Llc

(2.1012%)

since

2025/06/30

13.

Nordea Investment Mgmt Bank Demark A/s

(1.8864%)

since

2025/06/30

14.

Dimensional Fund Advisors, Inc.

(1.7802%)

since

2025/06/30

15.

Geode Capital Management, LLC

(1.6909%)

since

2025/06/30

16.

Vanguard Small Cap Value Index Inv

(1.5577%)

since

2025/07/31

17.

MFS Mid Cap Value Equity

(1.5231%)

since

2025/06/30

18.

MFS Mid Cap Value A

(1.5022%)

since

2025/07/31

19.

Charles Schwab Investment Management Inc

(1.3784%)

since

2025/06/30

20.

Bank of New York Mellon Corp

(1.377%)

since

2025/06/30

21.

Kahn Brothers & CO Inc /DE/

(1.3425%)

since

2025/06/30

22.

AQR Capital Management LLC

(1.252%)

since

2025/06/30

23.

Private Management Group Inc

(1.2063%)

since

2025/06/30

24.

Vanguard Institutional Extnd Mkt Idx Tr

(1.075%)

since

2025/07/31

25.

Gotham Asset Management, LLC

(1.0407%)

since

2025/06/30

26.

iShares S&P Small-Cap 600 Value ETF

(0.9321%)

since

2025/08/31

28.

Brandywine Global Investment Mgmt LLC

(0.8704%)

since

2025/06/30

29.

Northern Trust Corp

(0.8001%)

since

2025/06/30

30.

Vanguard Tax-Managed Small Cap Adm

(0.707%)

since

2025/07/31

31.

Vanguard Equity-Income Inv

(0.687%)

since

2025/06/30

32.

Russell Inv Tax-Managed US Large Cap S

(0.6744%)

since

2025/07/31

33.

First Trust Health Care AlphaDEX® ETF

(0.6195%)

since

2025/08/28

34.

SPDR® S&P 600 Small Cap Value ETF

(0.5711%)

since

2025/08/31

35.

Fidelity Extended Market Index

(0.5424%)

since

2025/07/31

36.

WisdomTree US SmallCap Dividend ETF

(0.5315%)

since

2025/08/29

37.

Nordea 1 - Glb Sust Stars Equity BI USD

(0.5124%)

since

2025/07/31

38.

Schwab US Small-Cap ETF™

(0.4748%)

since

2025/08/30

39.

Principal SmallCap S&P 600 Idx SP

(0.3946%)

since

2025/07/31

40.

Vanguard High Dividend Yield ETF

(0.3834%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

1.01

EPS Estimate

0.93

EPS Difference

0.08

Surprise Percent

8.6022%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7)
Defensive
Highly Defensive(7.5)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(7.3)
GARP
Fair GARP(6)
Growth
Moderate Growth(4.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Moderate Quality(5.5)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.